# Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer

> **NCT02910050** · PHASE2 · UNKNOWN · sponsor: **Xu fei** · enrollment: 58 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Bicalutamide
- **DRUG:** Aromatase Inhibitor

## Key facts

- **NCT ID:** NCT02910050
- **Lead sponsor:** Xu fei
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2018-09
- **Final completion:** 2018-12
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2017-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02910050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02910050, "Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02910050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*